Search

Your search keyword '"Hatano, Taku"' showing total 663 results
Start Over Author "Hatano, Taku"
663 results on '"Hatano, Taku"'

2. Digital detection of Alzheimer’s disease using smiles and conversations with a chatbot

Author

Takeshige-Amano, Haruka, Oyama, Genko, Ogawa, Mayuko, Fusegi, Keiko, Kambe, Taiki, Shiina, Kenta, Ueno, Shin-ichi, Okuzumi, Ayami, Hatano, Taku, Motoi, Yumiko, Kawakami, Ito, Ando, Maya, Nakayama, Sachiko, Ishida, Yoshinori, Maei, Shun, Lu, Xiangxun, Kobayashi, Tomohisa, Wooden, Rina, Ota, Susumu, Morito, Ken, Ito, Yoshitaka, Nakajima, Yoshihiro, Yoritaka, Asako, Kato, Tadafumi, and Hattori, Nobutaka

Published
2024
Full Text
View/download PDF

4. Impact of Istradefylline on Levodopa Dose Escalation in Parkinson’s Disease: ISTRA ADJUST PD Study, a Multicenter, Open-Label, Randomized, Parallel-Group Controlled Study

Author

Hatano, Taku, Sengoku, Renpei, Nagayama, Hiroshi, Yanagisawa, Naotake, Yoritaka, Asako, Suzuki, Keisuke, Nishikawa, Noriko, Mukai, Yohei, Nomura, Kyoichi, Yoshida, Norihito, Seki, Morinobu, Matsukawa, Miho Kawabe, Terashi, Hiroo, Kimura, Katsuo, Tashiro, Jun, Hirano, Shigeki, Murakami, Hidetomo, Joki, Hideto, Uchiyama, Tsuyoshi, Shimura, Hideki, Ogaki, Kotaro, Fukae, Jiro, Tsuboi, Yoshio, Takahashi, Kazushi, Yamamoto, Toshimasa, Kaida, Kenichi, Ihara, Ryoko, Kanemaru, Kazutomi, and Kano, Osamu

Published
2024
Full Text
View/download PDF

10. Analytical and clinical validity of wearable, multi-sensor technology for assessment of motor function in patients with Parkinson’s disease in Japan

Author

Oyama, Genko, Burq, Maximilien, Hatano, Taku, Marks, Jr, William J., Kapur, Ritu, Fernandez, Jovelle, Fujikawa, Keita, Furusawa, Yoshihiko, Nakatome, Keisuke, Rainaldi, Erin, Chen, Chen, Ho, King Chung, Ogawa, Takashi, Kamo, Hikaru, Oji, Yutaka, Takeshige-Amano, Haruka, Taniguchi, Daisuke, Nakamura, Ryota, Sasaki, Fuyuko, Ueno, Shinichi, Shiina, Kenta, Hattori, Anri, Nishikawa, Noriko, Ishiguro, Mayu, Saiki, Shinji, Hayashi, Ayako, Motohashi, Masatoshi, and Hattori, Nobutaka

Published
2023
Full Text
View/download PDF

11. Propagative α-synuclein seeds as serum biomarkers for synucleinopathies

Author

Okuzumi, Ayami, Hatano, Taku, Matsumoto, Gen, Nojiri, Shuko, Ueno, Shin-ichi, Imamichi-Tatano, Yoko, Kimura, Haruka, Kakuta, Soichiro, Kondo, Akihide, Fukuhara, Takeshi, Li, Yuanzhe, Funayama, Manabu, Saiki, Shinji, Taniguchi, Daisuke, Tsunemi, Taiji, McIntyre, Deborah, Gérardy, Jean-Jacques, Mittelbronn, Michel, Kruger, Rejko, Uchiyama, Yasuo, Nukina, Nobuyuki, and Hattori, Nobutaka

Published
2023
Full Text
View/download PDF

14. Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders

Author

Pilotto, Andrea, Romagnolo, Alberto, Scalvini, Andrea, Masellis, Mario, Shimo, Yasushi, Bonanni, Laura, Camicioli, Richard, Wang, Lily L, Dwivedi, Alok K, Longardner, Katherine, Rodriguez-Porcel, Federico, DiFrancesco, Mark, Vizcarra, Joaquin A, Montanaro, Elisa, Maule, Simona, Lupini, Alessandro, Ojeda-López, Carmen, Black, Sandra E, Delli Pizzi, Stefano, Gee, Myrlene, Tanaka, Ryota, Yamashiro, Kazuo, Hatano, Taku, Borroni, Barbara, Gasparotti, Roberto, Rizzetti, Maria C, Hattori, Nobutaka, Lopiano, Leonardo, Litvan, Irene, Espay, Alberto J, Padovani, Alessandro, and Merola, Aristide

Subjects
Parkinson's Disease, Acquired Cognitive Impairment, Neurodegenerative, Brain Disorders, Aging, Neurosciences, Clinical Research, Dementia, Neurological, Aged, Aged, 80 and over, Atrophy, Female, Humans, Hypotension, Orthostatic, Lewy Body Disease, Magnetic Resonance Imaging, Male, Middle Aged, Parkinson Disease, Severity of Illness Index, Temporal Lobe, White Matter, Clinical Sciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

ObjectiveTo evaluate whether orthostatic hypotension (OH) or supine hypertension (SH) is associated with brain atrophy and white matter hyperintensities (WMH), we analyzed clinical and radiologic data from a large multicenter consortium of patients with Parkinson disease (PD) and dementia with Lewy bodies (DLB).MethodsSupine and orthostatic blood pressure (BP) and structural MRI data were extracted from patients with PD and DLB evaluated at 8 tertiary-referral centers in the United States, Canada, Italy, and Japan. OH was defined as a systolic/diastolic BP fall ≥20/10 mm Hg within 3 minutes of standing from the supine position (severe ≥30/15 mm Hg) and SH as a BP ≥140/90 mm Hg with normal sitting BP. Diagnosis-, age-, sex-, and disease duration-adjusted differences in global and regional cerebral atrophy and WMH were appraised with validated semiquantitative rating scales.ResultsA total of 384 patients (310 with PD, 74 with DLB) met eligibility criteria, of whom 44.3% (n = 170) had OH, including 24.7% (n = 42) with severe OH and 41.7% (n = 71) with SH. OH was associated with global brain atrophy (p = 0.004) and regional atrophy involving the anterior-temporal (p = 0.001) and mediotemporal (p = 0.001) regions, greater in severe vs nonsevere OH (p = 0.001). The WMH burden was similar in those with and without OH (p = 0.49). SH was not associated with brain atrophy (p = 0.59) or WMH (p = 0.72).ConclusionsOH, but not SH, was associated with cerebral atrophy in Lewy body disorders, with prominent temporal region involvement. Neither OH nor SH was associated with WMH.

Published
2021

15. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Author

Höglinger, Günter U, Litvan, Irene, Mendonca, Nuno, Wang, Deli, Zheng, Hui, Rendenbach-Mueller, Beatrice, Lon, Hoi-Kei, Jin, Ziyi, Fisseha, Nahome, Budur, Kumar, Gold, Michael, Ryman, Davis, Florian, Hana, Investigators, Arise, Ahmed, Anwar, Aiba, Ikuko, Albanese, Alberto, Bertram, Kelly, Bordelon, Yvette, Bower, James, Brosch, Jared, Claassen, Daniel, Colosimo, Carlo, Corvol, Jean-Christophe, Cudia, Paola, Daniele, Antonio, Defebvre, Luc, Driver-Dunckley, Erika, Duquette, Antoine, Eleopra, Roberto, Eusebio, Alexandre, Fung, Victor, Geldmacher, David, Golbe, Lawrence, Grandas, Francisco, Hall, Deborah, Hatano, Taku, Honig, Lawrence, Hui, Jennifer, Kerwin, Diana, Kikuchi, Akio, Kimber, Thomas, Kimura, Takashi, Kumar, Rajeev, Ljubenkov, Peter, Lorenzl, Stefan, Ludolph, Albert, Mari, Zoltan, McFarland, Nikolaus, Meissner, Wassilios, Rivera, Pablo Mir, Mochizuki, Hidek, Morgan, John, Munhoz, Renato, Nishikawa, Noriko, O`Sullivan, John, Oeda, Tomoko, Oizumi, Hideki, Onodera, Osamu, Ory-Magne, Fabienne, Peckham, Elizabeth, Postuma, Ronald, Quattrone, Aldo, Quinn, Joseph, Ruggieri, Stefano, Sarna, Justyna, Schulz, Paul E, Slevin, John, Tagliati, Michele, Wile, Daryl, Wszolek, Zbigniew, Xie, Tao, and Zesiewicz, Theresa

Subjects
Biomedical and Clinical Sciences, Neurosciences, Clinical Sciences, Brain Disorders, Clinical Research, Clinical Trials and Supportive Activities, Patient Safety, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Neurological, Administration, Intravenous, Aged, Antibodies, Monoclonal, Humanized, Double-Blind Method, Female, Humans, Male, Middle Aged, Supranuclear Palsy, Progressive, Treatment Outcome, tau Proteins, Arise Investigators, Neurology & Neurosurgery, Clinical sciences
Abstract

BackgroundProgressive supranuclear palsy is a neurodegenerative disorder associated with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds to the N-terminus of human tau. We assessed the safety and efficacy of tilavonemab for the treatment of progressive supranuclear palsy.MethodsWe did a phase 2, multicentre, randomised, placebo-controlled, double-blind study at 66 hospitals and clinics in Australia, Canada, France, Germany, Italy, Japan, Spain, and the USA. Participants (aged ≥40 years) diagnosed with possible or probable progressive supranuclear palsy who were symptomatic for less than 5 years, had a reliable study partner, and were able to walk five steps with minimal assistance, were randomly assigned (1:1:1) by interactive response technology to tilavonemab 2000 mg, tilavonemab 4000 mg, or matching placebo administered intravenously on days 1, 15, and 29, then every 28 days through to the end of the 52-week treatment period. Randomisation was done by the randomisation specialist of the study sponsor, who did not otherwise participate in the study. The sponsor, investigators, and participants were unaware of treatment allocations. The primary endpoint was the change from baseline to week 52 in the Progressive Supranuclear Palsy Rating Scale (PSPRS) total score in the intention-to-treat population. Adverse events were monitored in participants who received at least one dose of study drug. Prespecified interim futility criteria were based on a model-based effect size of 0 or lower when 60 participants had completed the 52-week treatment period and 0·12 or lower when 120 participants had completed the 52-week treatment period. This study is registered at ClinicalTrials.gov, number NCT02985879.FindingsBetween Dec 12, 2016, and Dec 31, 2018, 466 participants were screened, 378 were randomised. The study was terminated on July 3, 2019, after prespecified futility criteria were met at the second interim analysis. A total of 377 participants received at least one dose of study drug and were included in the efficacy and safety analyses (2000 mg, n=126; 4000 mg, n=125; placebo, n=126). Least squares mean change from baseline to week 52 in PSPRS was similar in all groups (between-group difference vs placebo: 2000 mg, 0·0 [95% CI -2·6 to 2·6], effect size 0·000, p>0·99; 4000 mg, 1·0 [-1·6 to 3·6], -0·105, p=0·46). Most participants reported at least one adverse event (2000 mg, 111 [88%]; 4000 mg, 111 [89%]; placebo, 108 [86%]). Fall was the most common adverse event (2000 mg, 42 [33%]; 4000 mg, 54 [43%]; placebo, 49 [39%]). Proportions of patients with serious adverse events were similar among groups (2000 mg, 29 [23%]; 4000 mg, 34 [27%]; placebo, 33 [26%]). Fall was the most common treatment-emergent serious adverse event (2000 mg, five [4%]; 4000 mg, six [5%]; placebo, six [5%]). 26 deaths occurred during the study (2000 mg, nine [7%]; 4000 mg, nine [7%]; placebo, eight [6%]) but none was drug related.InterpretationA similar safety profile was seen in all treatment groups. No beneficial treatment effects were recorded. Although this study did not provide evidence of efficacy in progressive supranuclear palsy, the findings provide potentially useful information for future investigations of passive immunisation using tau antibodies for progressive supranuclear palsy.FundingAbbVie Inc.

Published
2021

18. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

Author

Genge, Angela, Massie, Rami, Berube, Maxime, Bril, Vera, Daniyal, Lubna, Mannan, Shabber, Ng, Eduardo, Raman, Ritesh Rohan Raghu, Sarpong, Evelyn, Alcantara, Monica, Dionne, Annie, Siddiqi, Zaeem, Blackmore, Derrick, Hussain, Faraz, Matte, Genevieve, Botez, Stephan, Tyblova, Michaela, Jakubikova, Michala, Junkerova, Jana, Vissing, John, Witting, Nanna, Holm-Yildiz, Sonja, Stemmerik, Mads, Andersen, Henning, Obál, Izabella, Solé, Guilhem, Mathis, Stéphane, Violleau, Marie-Hélène, Tranchant, Christine, Messai, Sihame, Chanson, Jean-Baptiste, Nadaj-Pakleza, Aleksandra, Verloes, Arnaud, Zaidi, Leila, Sacconi, Sabrina, Gambella, Manuela, Cavalli, Michele, Stojkovic, Tanya, Demeret, Sophie, Le Guennec, Loic, Querin, Giorgia, Weiss, Nicolas, Masingue, Marion, Magy, Laurent, Ghorab, Karima, Rukhadze, Ia, Tsiskaridze, Alexander, Janelidze, Marina, Margania, Temur, Then Bergh, Florian, Hänsel, Eike, Kalb, Andrea, Meilick, Bianca, Reuschel, Mandy, Teußer, Lars-Malte, Unterlauft, Astrid, Goedel, Clemens, Hagenacker, Tim, Totzeck, Andreas, Stolte, Benjamin, Blaes, Franz, Bindler, Christine, Tsoutsikas, Vasilios, Roediger, Annekathrin, Geis, Christian, Schmidt, Jens, Zschüntzsch, Jana, Schwarz, Margret, Meyer, Stefanie, Kummer, Karsten, Glaubitz, Stefanie, Zeng, Rachel, Wiendl, Heinz, Klotz, Luisa, Lammerskitten, Anna, Lünemann, Jan, Diószeghy, Péter, Mantegazza, Renato, Maggi, Lorenzo, Rinaldi, Elena, Gastaldi, Matteo, Mazzacane, Federico, Businaro, Pietro, Iorio, Raffaele, Antonini, Giovanni, Fionda, Laura, Rinaldi, Rita, Rossi, Simone, Habetswallner, Francesco, Tuccillo, Francesco, Umehara, Haruna, Uenaka, Eiko, Takahashi, Masanori, Higashi, Keiko, Kinoshita, Makoto, Yoneda, Emika, Nakamura, Noriko, Fujita, Saeka, Kubota, Tomoya, Ono, Masami, Yamamoto, Sana, Hatano, Taku, Oikoshi, Kazuki, Yokoyama, Kazumasa, Oji, Yutaka, Tomizawa, Yuji, Uzawa, Akiyuki, Yasuda, Manato, Akita, Sachiko, Ozawa, Yukiko, Onishi, Yosuke, Takaki, Miki, Yamada, Hiromi, Minemoto, Kanako, Sanko, Miki, Izawa, Nanae, Nakayama, Mayumi, Masuda, Masayuki, Tsuji, Rune, Ido, Nobuhiro, Hyodo, Yumi, Okubo, Yoshihiko, Minohara, Akiko, Haraguchi, Nana, Naito, Makiko, Yoshida, Seiko, Fukushige, Yuri, Tsujino, Akira, Nagaoka, Atsushi, Miyazaki, Teiichiro, Yoshimura, Shunsuke, Hirayama, Takuro, Shima, Tomoaki, Okamoto, Naoko, Matsumoto, Riki, Sekiguchi, Kenji, Ueda, Takehiro, Chihara, Norio, Kirimura, Mari, Sunagawa, Emi, Suzuki, Ayaka, Suzuki, Shigeaki, Wada, Aozora, Ishizuchi, Kei, Suzuki, Yasushi, Yata, Mitsuo, Komatsu, Yuka, Tsukita, Kenichi, Watanabe, Genya, Sato, Kazuki, Kawasaki, Emiko, Yamamoto, Naoki, Ono, Hirohiko, Tsuda, Tomoko, Ohashi, Shigeki, Utsugisawa, Kimiaki, Fujisawa, Yuka, Yokota, Yumiko, Nagane, Yuriko, Ayumi, Kameda, Takematsu, Yuka, Naito, Hiroyuki, Sugimoto, Takamichi, Kuwada, Kumiko, Rejdak, Konrad, Szklener, Sebastian, Kitowska, Monika, Derkacz, Kandyda, Druzdz, Artur, Berkowicz, Tomasz, Budzinska, Paulina, Halas, Marek, Zaslavskiy, Leonid, Skornyakova, Evgeniya, Kotov, Sergey, Novikova, Ekaterina, Sidorova, Olga, Goldobin, Vitalii, Alekseeva, Tatiana, Isabekova, Patimat, Malkova, Nadezhda, Korobko, Denis, Djordjevic, Gordana, Stojanov, Aleksandar, Peric, Stojan, Lavrnic, Dragana, Bozovic, Ivo, Palibrk, Aleksa, Casasnovas, Carlos, Nedkova-Hristova, Velina, Vidal Fernández, Nuria, Cortés Vicente, Elena, Querol Gutiérrez, Luis, Salvadó Figueras, Maria, Canovas Segura, Anna, Juntas Morales, Raúl, Sanchez Tejerina, Daniel, Saiz, Albert, Blanco Morgado, Yolanda, Llufriú Durán, Sara, Sepúlveda Gázquez, María, Martínez Hernández, Eugenia María, Gutiérrez Gutiérrez, Gerardo, Iniesta, Paqui, Meca Lallana, José, Guo, Yuh-Cherng, Chiu, Hou-Chang, Yeh, Jiann-Horng, Chen, Ya Hui, Lee, Mei Fen, Lee, Yi-Chung, Lai, Kuan Lin, Beydoun, Said, Akhter, Salma, Vu, Tuan, Lam, Lucy, Thomas, Alisha, Rivner, Michael, Quarles, Brandy, Lange, Dale, Holzberg, Shara, Pavlakis, Pantelis, Goutham, Ashwathy, Kaminski, Henry, Aly, Radwa, Ashworth, Lisa, Bender, Kathryn, Bond, Karie, Buckner, Joanne, Byerly, Sara, Caress, James, Clemons, Jessyca, Farmer, Asha, Franklin, Catherine, Harris, Summer, Hiatt, Meredith, Gandhi Mehta, Rachana, Miller, Gina, Smith, Lynn, Smith, Rose, Strittmatter, Brian, Mozaffar, Tahseen, Habib, Ali A, Hernandez, Isela, Moulton, Kelsey, Karam, Chafic, Ravikumar, Pranali, Lomen-Hoerth, Catherine, Rosow, Laura, George, Hannah, Irodenko, Viktoriya, Kang, Min, Denny, Carol, Hanson, Bart, Klein, Sara, Martinez-Thompson, Jennifer, Naddaf, Elie, Padgett, Denny, Sorenson, Eric, L Sultze, Jane, Weis, Delena, Rezania, Kourosh, Thonhoff, Jason, Shroff, Sheetal, Pascuzzi, Robert, Micheels, Angela, Bodkin, Cynthia, Comer, Adam, Baras, Gelasio, Wagner, Renee, Mahuwala, Zabeen, Ryan, Stephen, Su, Kai, Sharma, Khema, Brown, Andrew, Liow, Kore, Drużdż, Artur, Grosskreutz, Julian, Boehnlein, Marion, Bozorg, Ali, Gayfieva, Maryam, Greve, Bernhard, Woltering, Franz, and Kaminski, Henry J

Published
2023
Full Text
View/download PDF

19. Idiopathic rapid eye movement sleep behavior disorder in Japan: An observational study

Author

Nishikawa, Noriko, Murata, Miho, Hatano, Taku, Mukai, Yohei, Saitoh, Yuji, Sakamoto, Takashi, Hanakawa, Takashi, Kamei, Yuichi, Tachimori, Hisateru, Hatano, Kenji, Matsuda, Hiroshi, Taruno, Yosuke, Sawamoto, Nobukatsu, Kajiyama, Yuta, Ikenaka, Kensuke, Kawabata, Kazuya, Nakamura, Tomohiko, Iwaki, Hirotaka, Kadotani, Hiroshi, Sumi, Yukiyoshi, Inoue, Yuichi, Hayashi, Toshihiro, Ikeuchi, Takeshi, Shimo, Yasushi, Mochizuki, Hideki, Watanabe, Hirohisa, Hattori, Nobutaka, Takahashi, Yuji, and Takahashi, Ryosuke

Published
2022
Full Text
View/download PDF

23. Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson’s disease: study protocol for the ISTRA ADJUST PD randomized, controlled study

Author

Hatano, Taku, Kano, Osamu, Sengoku, Renpei, Yoritaka, Asako, Suzuki, Keisuke, Nishikawa, Noriko, Mukai, Yohei, Nomura, Kyoichi, Yoshida, Norihito, Seki, Morinobu, Matsukawa, Miho Kawabe, Terashi, Hiroo, Kimura, Katsuo, Tashiro, Jun, Hirano, Shigeki, Murakami, Hidetomo, Joki, Hideto, Uchiyama, Tsuyoshi, Shimura, Hideki, Ogaki, Kotaro, Fukae, Jiro, Tsuboi, Yoshio, Takahashi, Kazushi, Yamamoto, Toshimasa, Yanagisawa, Naotake, and Nagayama, Hiroshi

Published
2022
Full Text
View/download PDF

24. Exercise Habits in People with Parkinson's: A Multinational Survey.

Author

Jagota, Priya, Phutrakool, Phanupong, Kamble, Nitish, Dang, Thuong Huyen Thi, Aldaajani, Zakiyah, Hatano, Taku, Hoskere Sreenivasa, Deva Kumar, Tripura, Telugu, Kukkle, Prashanth Lingappa, Jeon, Beomseok, Nishikawa, Noriko, Oji, Yutaka, Tran, Tai Ngoc, Susatia, Frandy, Fabbri, Margherita, Leung, Clémence, Alonso Canovas, Araceli, Kamel, Walaa A., Pal, Pramod Kumar, and Rakesh, Kempaiah

Subjects
PARKINSON'S disease, PHYSICAL mobility, BACHELOR'S degree, QUALITY of life, AGE of onset
Abstract

Background: Exercise has been demonstrated to result in improvements in physical function, cognition, and quality of life in People with Parkinson's (PwP) but its adoption is variable. Objectives: To investigate exercise preferences, levels, influencing factors among a diverse Parkinson's disease (PD) population, to understand exercise adoption patterns and plan informed interventions. Methods: A cross‐sectional survey collected data through online platforms and paper‐based methods. The Exercise Index (ExI) calculated exercise level based on frequency and duration. Results: Of 2976 PwP, 40.6% exercised regularly, 38.3% occasionally, and 21.2% did not exercise. The overall mean ExI was 18.99 ± 12.37. Factors associated with high exercise levels included exercising in groups (ExI 24–26), weightlifting (ExI 27 (highest)), using muscle‐building equipment (ExI 25–26), and exercising at home following an app (ExI 26). A positive trend between ExI and varied exercise groups, locations, types, and equipment was observed. No expected benefit from exercise achieved the lowest ExI (8). Having at least two exercise‐promoting factors, a bachelor's degree or higher, receiving exercise advice at initial visits, and aged ≤40 years at PD onset were strong predictors of exercise (adjust OR = 7.814; 6.981; 4.170; 3.565). Falls and "other" most troublesome PD symptoms were negative predictors (aOR = 0.359; 0.466). Barriers to exercise did not predict the odds of exercise. Conclusions: The study shows that PwP's exercise behavior is influenced by their exercise belief, age at PD onset, doctor's advice at initial visits, education level, symptoms, and exercise‐promoting factors. High exercise levels were associated with certain types of exercises and exercising in groups. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Author

Ahmed, Anwar, Aiba, Ikuko, Albanese, Alberto, Bertram, Kelly, Bordelon, Yvette, Bower, James, Brosch, Jared, Claassen, Daniel, Colosimo, Carlo, Corvol, Jean-Christophe, Cudia, Paola, Daniele, Antonio, Defebvre, Luc, Driver-Dunckley, Erika, Duquette, Antoine, Eleopra, Roberto, Eusebio, Alexandre, Fung, Victor, Geldmacher, David, Golbe, Lawrence, Grandas, Francisco, Hall, Deborah, Hatano, Taku, Höglinger, Günter U, Honig, Lawrence, Hui, Jennifer, Kerwin, Diana, Kikuchi, Akio, Kimber, Thomas, Kimura, Takashi, Kumar, Rajeev, Litvan, Irene, Ljubenkov, Peter, Lorenzl, Stefan, Ludolph, Albert, Mari, Zoltan, McFarland, Nikolaus, Meissner, Wassilios, Mir Rivera, Pablo, Mochizuki, Hidek, Morgan, John, Munhoz, Renato, Nishikawa, Noriko, O`Sullivan, John, Oeda, Tomoko, Oizumi, Hideki, Onodera, Osamu, Ory-Magne, Fabienne, Peckham, Elizabeth, Postuma, Ronald, Quattrone, Aldo, Quinn, Joseph, Ruggieri, Stefano, Sarna, Justyna, Schulz, Paul E, Slevin, John, Tagliati, Michele, Wile, Daryl, Wszolek, Zbigniew, Xie, Tao, Zesiewicz, Theresa, Mendonca, Nuno, Wang, Deli, Zheng, Hui, Rendenbach-Mueller, Beatrice, Lon, Hoi-Kei, Jin, Ziyi, Fisseha, Nahome, Budur, Kumar, Gold, Michael, Ryman, Davis, and Florian, Hana

Published
2021
Full Text
View/download PDF

31. Efficacy and Safety of Elobixibat in Parkinson's Disease with Chronic Constipation: CONST‐PD Study

Author

Hatano, Taku, primary, Oyama, Genko, additional, Shimo, Yasushi, additional, Ogaki, Kotaro, additional, Nishikawa, Noriko, additional, Nakamura, Ryota, additional, Tsunemi, Taiji, additional, Ogawa, Takashi, additional, Eguchi, Hiroto, additional, Daida, Kensuke, additional, Kurita, Naohide, additional, Ueno, Shin‐ichi, additional, Fukae, Jiro, additional, Sako, Wataru, additional, Shiina, Kenta, additional, Nakajima, Sho, additional, Oji, Yutaka, additional, Wakamori, Ryo, additional, Saiki, Shinji, additional, Nishioka, Kenya, additional, Okuzumi, Ayami, additional, Taniguchi, Daisuke, additional, Takeshige‐Amano, Haruka, additional, Fuse, Atsuhito, additional, Nakajima, Asuka, additional, Kano, Masayoshi, additional, Kamo, Hikaru, additional, Yamashita, Yuri, additional, Shindo, Atsuhiko, additional, Yanagisawa, Naotake, additional, and Hattori, Nobutaka, additional

Published
2024
Full Text
View/download PDF

32. Factor analysis for construct validity of a trunk impairment scale in Parkinson’s disease: a cross-sectional study

Author

Sato, Kazunori, primary, Yamazaki, Yuta, additional, Kameyama, Yoshihiro, additional, Watanabe, Koji, additional, Kitahara, Eriko, additional, Haruyama, Koshiro, additional, Takahashi, Yoko, additional, Fujino, Yuji, additional, Yamaguchi, Tomofumi, additional, Matsuda, Tadamitsu, additional, Makabe, Hitoshi, additional, Isayama, Reina, additional, Murakami, Yuhei, additional, Tani, Mami, additional, Honaga, Kaoru, additional, Hatori, Kozo, additional, Oji, Yutaka, additional, Tomizawa, Yuji, additional, Hatano, Taku, additional, Hattori, Nobutaka, additional, and Fujiwara, Toshiyuki, additional

Published
2024
Full Text
View/download PDF

33. Parkinson’s disease-associated iPLA2-VIA /PLA2G6 regulates neuronal functions and α-synuclein stability through membrane remodeling

Author

Mori, Akio, Hatano, Taku, Inoshita, Tsuyoshi, Shiba-Fukushima, Kahori, Koinuma, Takahiro, Meng, Hongrui, Kubo, Shin-ichiro, Spratt, Spencer, Cui, Changxu, Yamashita, Chikara, Miki, Yoshimi, Yamamoto, Kei, Hirabayashi, Tetsuya, Murakami, Makoto, Takahashi, Yoshikazu, Shindou, Hideo, Nonaka, Takashi, Hasegawa, Masato, Okuzumi, Ayami, Imai, Yuzuru, and Hattori, Nobutaka

Published
2019

39. α-Synuclein Seeding Assay Using RT-QuIC

Author

Okuzumi, Ayami, primary, Hatano, Taku, additional, Fukuhara, Takeshi, additional, Ueno, Shinichi, additional, Nukina, Nobuyuki, additional, Imai, Yuzuru, additional, and Hattori, Nobutaka, additional

Published
2021
Full Text
View/download PDF

44. Distinct mechanisms of axonal globule formation in mice expressing human wild type ¿-synuclein or dementia with Lewy bodies-linked P123H ß-synuclein

Author

Sekigawa, Akio, Fujita, Masayo, Sekiyama, Kazunari, Takamatsu, Yoshiki, Hatano, Taku, Rockenstein, Edward, La Spada, Albert R, Masliah, Eliezer, and Hashimoto, Makoto

Abstract

Abstract Background Axonopathy is critical in the early pathogenesis of neurodegenerative diseases, including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Axonal swellings such as globules and spheroids are a distinct feature of axonopathy and our recent study showed that transgenic (tg) mice expressing DLB-linked P123H β-synuclein (P123H βS) were characterized by P123H βS-immunoreactive axonal swellings (P123H βS-globules). Therefore, the objectives of this study were to evaluate α-synuclein (αS)-immunoreactive axonal swellings (αS-globules) in the brains of tg mice expressing human wild-type αS and to compare them with the globules in P123H βS tg mice. Results In αS tg mice, αS-globules were formed in an age-dependent manner in various brain regions, including the thalamus and basal ganglia. These globules were composed of autophagosome-like membranous structures and were reminiscent of P123H βS-globules in P123H βS tg mice. In the αS-globules, frequent clustering and deformation of mitochondria were observed. These changes were associated with oxidative stress, based on staining of nitrated αS and 4-hydroxy-2-nonenal (4-HNE). In accord with the absence of mitochondria in the P123H βS-globules, staining of nitrated αS and 4-HNE in these globules was weaker than that for αS-globules. Leucine-rich repeat kinase 2 (LRRK2), the PARK8 of familial PD, was detected exclusively in αS-globules, suggesting a specific role of this molecule in these globules. Conclusions Lysosomal pathology was similarly observed for both αS- and P123H βS-globules, while oxidative stress was associated with the αS-globules, and to a lesser extent with the P123H βS-globules. Other pathologies, such as mitochondrial alteration and LRRK2 accumulation, were exclusively detected for αS-globules. Collectively, both αS- and P123H βS-globules were formed through similar but distinct pathogenic mechanisms. Our findings suggest that synuclein family members might contribute to diverse axonal pathologies.

Published
2012

47. Connection between drug-mediated neurotransmission and salivary microbiome

Author

Hisamatsu, Daisuke, primary, Ogata, Yusuke, additional, Takeshige-Amano, Haruka, additional, Suda, Wataru, additional, Hatano, Taku, additional, Asaoka, Daisuke, additional, Mabuchi, Yo, additional, Naraoka, Yuna, additional, Sato, Nobuhiro, additional, Asada, Takashi, additional, Hattori, Nobutaka, additional, Hattori, Masahira, additional, and Akazawa, Chihiro, additional

Published
2023
Full Text
View/download PDF

48. Characterizing restless legs syndrome and leg motor restlessness in patients with Parkinson's disease: A multicenter case-controlled study

Author

Kadowaki, Taro, Yamamoto, Tatsuya, Hatano, Taku, Miyamoto, Tomoyuki, Suzuki, Shiho, Watanabe, Yuka, Shimura, Hideki, Urabe, Takao, Suzuki, Keisuke, Okuma, Yasuyuki, Uchiyama, Tomoyuki, Miyamoto, Masayuki, Sakakibara, Ryuji, Shimo, Yasushi, Hattori, Nobutaka, Kuwabara, Satoshi, Yamamoto, Toshimasa, Kaji, Yoshiaki, Hirano, Shigeki, Numao, Ayaka, and Hirata, Koichi

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results